HMO expansion: Jennewein Biotechnologie to strengthen portfolio with Arthus Mineralsprings facility buy
09 0ct 2018 --- Jennewein Biotechnologie is to expand its production of human milk oligosaccharides (HMO) from its current portfolio of two products to include five more. The expansion is facilitated through the company's acquisition of the former facilities of Arthus Mineralsprings in Bad Hönningen, Germany. Jennewein plans to build a new integrated fermentation and recovery plant for the production of HMOs. “With the new plant, we will be able to produce additional HMOs, expanding our current portfolio of two products (2′ fucosyllactose and lacto-N-neotetraose) to include five more (3′ fucosyllactose, difucosyllactose, lacto-N-tetraose, 6′-sialyllactose and 3′-sialyllactose),” says Benedikt Engels, Chief Operation Officer at Jennewein. “We have been searching for some time for a suitable location to establish an integrated HMO fermentation and recovery plant close to our current facility in Rheinbreitbach,” says Dr. Stefan Jennewein, CEO and Co-Founder of the company.  Click to Enlarge
portfolio from two to five ingredients. HMOs form the third most abundant solid component of human milk after lactose and fat and research increasingly demonstrates that much of breast milk's value lies within these components. HMOs have prebiotic properties and are incredibly complex to replicate, but are increasingly sought after in infant nutrition products. Jennewein will continue to focus on the infant and medical nutrition markets, but a spokesperson for the company tells NutritionInsight that the option for developing products in the adult nutrition area may be a future possibility too. The new integrated facility will combine fermentation and recovery, and will yield spray-dried HMO products. Jennewein Biotechnologie plans to build separate production lines for the manufacture of each of the new HMO products. “The new plant will become one of the largest fermentation facilities in central Europe,” adds Stephan Michel, Chief Financial Officer. Jennewein Biotechnologie is an international industrial biotechnology company with a range of products in the field of complex oligosaccharides (HMOs) and rare monosaccharides. In 2015, the US Food and Drug Administration (FDA) granted a license to market 2′-fucosyllactose in the US. This was followed in 2017 by European Union marketing authorization under the Novel Food Regulation. To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News New research links gut microbiome to ethnicity07 Dec 2018 --- The gut microbiome is closely linked to overall health and may vary according to ethnicity, joint research between Vanderbilt University, Tennessee, and the University of Minnesota, US, has found. However, the researchers point out that although foods and supplements that target the microbiome are currently gaining popularity, more research is needed to pinpoint what exactly constitutes a healthy gut microbiome. Health & Nutrition News Under plant-based pressure: “Plenty of room on the shelf,” say dairy ingredient suppliers06 Dec 2018 --- Interest in plant-based nutrition is showing no signs of slowing down, with The Plant Kingdom being one of Innova Market Insights’ Top Trends for 2019. Plant-based options are flourishing in a range of categories, with dairy alternatives, for example, on the rise. But what will this plant-centered NPD boom spell for dairy suppliers, as consumer interest turns toward the ever-growing range of non-dairy options? At HiE 2018 in Frankfurt, Germany, NutritionInsight spoke with a number of dairy ingredients suppliers to hear their views on plant-based NPD growth and how it will impact the dairy ingredients sector. Health & Nutrition News Whey protein among key drivers in infant nutrition purchasing, Arla study finds06 Dec 2018 --- Mothers searching for the optimal infant nutrition product are attracted to high-quality, whey protein options that support “‘healthy growth,” according to a YouGov survey commissioned by Arla Foods Ingredients. Spanning 5,658 mothers in seven different countries, the survey sought to uncover common global themes regarding what consumers – particularly generation X and millennials – want from their breast-milk substitute products. Health & Nutrition News The next infant formula staple? NZMP eyes milk fat globule membrane potential21 Nov 2018 --- As scientific understanding of infant development evolves, the industry is seeing growing opportunities for infant nutrition formulas that come as close to human breast milk as possible, and which benefit aspects such as brain and immune health. In this space, NZMP, Fonterra’s B2B ingredients business, is making strides in uncovering the potential of milk fat globule membrane (MFGM). Health & Nutrition News FrieslandCampina’s GOS powder linked to improved intestinal health in obese adults15 Nov 2018 --- FrieslandCampina’s Vivinal GOS Powder has been found to benefit obese people with intestinal problems. According to a recent study, consumption of the galacto-oligosaccharide ingredient may significantly reduce certain markers of gut permeability, indicating an improved intestinal barrier function. More Articles |
.jpg)
